Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson’s disease
✍ Scribed by Yu Watanabe; Hiroyuki Kato; Tsutomu Araki
- Publisher
- Springer
- Year
- 2007
- Tongue
- English
- Weight
- 556 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0885-7490
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
This is the first study to investigate the potential protective effects of the lipophilic kavapyrone (+/-)-kavain in the experimental MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease (PD). Male C57BL/6 mice were treated with (+/-)-kavain (50, 100, or 200 mg/kg i.p.) o
## Abstract A typical feature of Parkinson's disease is the progressive loss of dopaminergic neurons in the substantia nigra, in which inhibition of mitochondrial complex I activity may play an important role. Rotenone or 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) inhibit the mitochondrial
## Abstract Nitric oxide (NO) is a major signaling molecule in the retina and CNS, with physiological roles in every cell type in the retina. Previous work shows that neuronal nitric oxide synthase (nNOS) is an important source of NO in the vertebrate retina. There are distinct, active alternative